Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

NovaSterilis Inc. and Cornell researcher Dr. CC Chu awarded a Metropolitan Development Association grant

NovaSterilis, Lansing NY, and Dr. CC Chu were awarded a grant from the Metropolitan Development Association (MDA) to explore the feasibility of utilizing NovaSterilis supercritical co2 sterilization for a variety of absorbable biomaterials from both commercial and experimental sources.

11 Oct 2010

Access highlights clinical benefits of MuGard at ESMO conference

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.

11 Oct 2010

Generex to acquire majority interest in Global Medical Direct

Generex Biotechnology Corporation today announced that it has entered into a definitive agreement to acquire a majority interest (51%) in Global Medical Direct, LLC of Lenexa, Kansas, a nationwide Durable Medical Equipment and Pharmaceutical provider specializing in direct-to-consumer diabetes supplies and medications.

11 Oct 2010

FDA issues CRL for AZ-004 NDA application

Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for AZ-004 (Staccato loxapine), submitted as Adusuve Staccato (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.

8 Oct 2010

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

Cipher Pharmaceuticals Inc. today announced that the U.S. Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-TRAMADOL ER, the Company's extended-release tramadol product for the treatment of moderate to moderately severe chronic pain in adults.

8 Oct 2010

Trekkers and climbers face high risk for Acute Mountain Sickness

Climbers of high peaks such as Mount Kilimanjaro are at high risk for Acute Mountain Sickness (AMS). Trekkers should not ignore AMS warning signs, which can progress to more serious medical outcomes.

7 Oct 2010

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.

From Baxter International Inc. 6 Oct 2010

Pfizer announces review of strategic alternatives for Capsugel

Pfizer Inc. announced today that it is reviewing strategic alternatives for Capsugel, which may include a divestiture. Capsugel is a distinct business unit within Pfizer's Diversified Businesses segment and is the world's leading provider of hard capsules and an innovator in drug delivery systems.

6 Oct 2010

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

The Focused Ultrasound Surgery Foundation is hosting the 2nd International Symposium on MR-guided Focused Ultrasound in Chantilly, Virginia from October 17-20. Leading researchers and clinicians from around the world will gather at the three-day scientific conference to present and discuss the latest advancements in one of the most revolutionary and promising areas of therapeutic medicine.

6 Oct 2010

Gerresheimer third-quarter group revenues increase 9.5% to EUR 259.4M

Gerresheimer AG, one of the leading worldwide suppliers to the pharma and healthcare industry, is continuing its growth course in the financial year 2010. "Our business is developing well. We continue to focus on the field of pharma and healthcare. Doing so we are achieving solid and profitable growth," says Uwe Rohrhoff, CEO of Gerresheimer AG.

6 Oct 2010

Apricus Bio raises over $9.3 million in securities offering

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Company has closed its previously announced securities offering, raising over $9.3 million in gross proceeds. Apricus Bio intends to use the proceeds from this offering for product and technology development and general corporate purposes. Dawson James Securities acted as the exclusive placement agent for the offering.

5 Oct 2010

Tris Pharma receives FDA final approval for generic Tussionex ANDA

Par Pharmaceutical Companies, Inc. today announced that its licensing partner, Tris Pharma, Inc., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for hydrocodone polistirex and chlorpheniramine polistirex (CIII) extended-release (ER) oral suspension (equivalent to 10 mg of hydrocodone bitartrate and 8 mg of chlorpheniramine maleate per 5 mL).

5 Oct 2010

TMNG Global and Scientia Advisors partner to offer strategic consulting services for home health sector

TMNG Global a leading provider of professional services to the global communications, digital media, technology, and financial services industries, and Scientia Advisors, a global management consulting firm specializing in healthcare, life science, nutrition and biotechnology, today announced a partnership to offer strategic consulting services for the emerging home health sector.

5 Oct 2010

Agile completes enrollment in AG200-15 Phase 3 contraceptive patch study

Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.

4 Oct 2010

FDA provides Celsion guidance for Thermodox NDA to treat primary liver cancer

Celsion Corporation, a leading oncology drug development company, announced that the Company has reached agreement with the U.S. Food and Drug Administration (FDA) that the requirements for non-clinical studies have been met for the New Drug Application (NDA) of ThermoDox.

4 Oct 2010

CWRU researcher receives New Innovator Award to advance synthetic platelet technology

A Case Western Reserve University researcher will receive a $2.3 million New Innovator Award today to further develop and broaden the uses of synthetic platelets and the technology that makes them work.

4 Oct 2010

Celsion presents Phase I/II DIGNITY trial data at 2010 Breast Cancer Symposium

Celsion Corporation announced today that interim data from its Phase I/II DIGNITY trial of ThermoDox in Recurrent Chest Wall (RCW) Breast Cancer were presented at the poster session at the 2010 Breast Cancer Symposium.

3 Oct 2010

Noven acquires global rights to Daytrana from Shire affiliates

Noven Pharmaceuticals, Inc. today announced that it has completed the acquisition of global rights to Daytrana® (methylphenidate transdermal system) from affiliates of Shire plc.

1 Oct 2010

DMC recommends continuation of enrollment in Celsion's Phase III ThermoDox HEAT study for primary liver cancer

Celsion Corporation, a leading oncology drug development company, announced that after reviewing data from 401 patients enrolled in its pivotal Phase III ThermoDox ® clinical study (the HEAT study) for primary liver cancer, the Data Monitoring Committee (DMC) has unanimously recommended that the trial continue to enroll patients with the goal of reaching the 600 patients required to complete the study.

1 Oct 2010